$MASI
MASIMO CORP

2020 Q3 Form 10-Q Financial Statement

#000093755620000171 Filed on October 27, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q4 2019 Q3
Revenue $278.1M $247.5M $229.0M
YoY Change 21.44% 10.93% 8.75%
Cost Of Revenue $99.19M $80.60M $72.74M
YoY Change 36.35% 7.75% 4.17%
Gross Profit $178.9M $166.9M $156.3M
YoY Change 14.5% 12.53% 11.02%
Gross Profit Margin 64.34% 67.44% 68.24%
Selling, General & Admin $90.38M $81.90M $80.35M
YoY Change 12.47% 10.38% 12.33%
% of Gross Profit 50.51% 49.06% 51.42%
Research & Development $28.85M $23.40M $24.28M
YoY Change 18.82% 18.18% 18.02%
% of Gross Profit 16.13% 14.02% 15.54%
Depreciation & Amortization $5.800M $5.900M $4.800M
YoY Change 20.83% 15.69% 20.0%
% of Gross Profit 3.24% 3.53% 3.07%
Operating Expenses $119.2M $105.4M $104.6M
YoY Change 13.95% 12.13% 13.6%
Operating Profit $59.70M $61.56M $51.63M
YoY Change 15.62% 14.19% 6.15%
Interest Expense $84.00K $2.800M $82.00K
YoY Change 2.44% 1071.43%
% of Operating Profit 0.14% 4.55% 0.16%
Other Income/Expense, Net $1.357M $0.00 $2.723M
YoY Change -50.17% -100.0% 164.88%
Pretax Income $61.06M $64.40M $54.36M
YoY Change 12.33% 15.83% 9.43%
Income Tax $11.65M $11.40M $5.270M
% Of Pretax Income 19.08% 17.7% 9.7%
Net Earnings $49.41M $52.92M $49.09M
YoY Change 0.65% 12.76% -14.08%
Net Earnings / Revenue 17.76% 21.38% 21.43%
Basic Earnings Per Share $0.90 $0.99 $0.92
Diluted Earnings Per Share $0.85 $0.92 $0.86
COMMON SHARES
Basic Shares Outstanding 55.00M shares 53.79M shares 53.54M shares
Diluted Shares Outstanding 58.28M shares 57.26M shares

Balance Sheet

Concept 2020 Q3 2019 Q4 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $719.1M $687.7M $633.4M
YoY Change 13.53% 24.47% 28.35%
Cash & Equivalents $669.1M $567.7M $513.4M
Short-Term Investments $50.00M $120.0M $120.0M
Other Short-Term Assets $88.27M $60.07M $60.77M
YoY Change 45.26% 85.26% 25.86%
Inventory $204.8M $115.9M $109.7M
Prepaid Expenses $29.47M $11.75M $10.05M
Receivables $146.9M $132.4M $130.4M
Other Receivables $34.20M $34.40M $29.90M
Total Short-Term Assets $1.159B $996.1M $934.2M
YoY Change 24.06% 26.2% 26.98%
LONG-TERM ASSETS
Property, Plant & Equipment $267.2M $219.6M $209.5M
YoY Change 27.55% 32.28% 27.25%
Goodwill $80.22M $22.35M $22.00M
YoY Change 264.69% -4.06% -6.21%
Intangibles $57.31M $27.25M $27.43M
YoY Change 108.9% -2.41% -3.62%
Long-Term Investments $7.950M $6.475M $6.287M
YoY Change 26.45% 439.58%
Other Assets $38.55M $28.79M $29.38M
YoY Change 31.2% 580.32% 661.29%
Total Long-Term Assets $554.2M $400.1M $380.0M
YoY Change 45.84% 9.44% 5.52%
TOTAL ASSETS
Total Short-Term Assets $1.159B $996.1M $934.2M
Total Long-Term Assets $554.2M $400.1M $380.0M
Total Assets $1.713B $1.396B $1.314B
YoY Change 30.36% 20.9% 19.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $89.53M $54.55M $40.77M
YoY Change 119.6% 35.06% 4.7%
Accrued Expenses $6.545M $6.115M $5.387M
YoY Change 21.5% 21.38% 13.96%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $232.8M $172.2M $150.0M
YoY Change 55.16% 17.51% 4.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.950M $56.04M $2.204M
YoY Change 79.22% 42.95% 2433.33%
Total Long-Term Liabilities $3.950M $56.04M $2.204M
YoY Change 79.22% 42.95% 2433.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $232.8M $172.2M $150.0M
Total Long-Term Liabilities $3.950M $56.04M $2.204M
Total Liabilities $298.3M $228.3M $205.9M
YoY Change 44.93% 22.88% 12.21%
SHAREHOLDERS EQUITY
Retained Earnings $1.271B $1.100B $1.048B
YoY Change 21.29% 18.2% 18.49%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $527.2M $526.6M $517.0M
YoY Change 1.98% 7.68% 5.71%
Treasury Stock Shares 15.53M shares 15.53M shares 15.46M shares
Shareholders Equity $1.415B $1.168B $1.108B
YoY Change
Total Liabilities & Shareholders Equity $1.713B $1.396B $1.314B
YoY Change 30.36% 20.9% 19.93%

Cashflow Statement

Concept 2020 Q3 2019 Q4 2019 Q3
OPERATING ACTIVITIES
Net Income $49.41M $52.92M $49.09M
YoY Change 0.65% 12.76% -14.08%
Depreciation, Depletion And Amortization $5.800M $5.900M $4.800M
YoY Change 20.83% 15.69% 20.0%
Cash From Operating Activities $40.40M $70.20M $50.60M
YoY Change -20.16% 11.08% 4.55%
INVESTING ACTIVITIES
Capital Expenditures -$10.20M -$13.50M -$9.700M
YoY Change 5.15% 136.84% 148.72%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $54.80M
YoY Change -100.0% -1665.71%
Cash From Investing Activities -$10.20M -$13.50M $45.10M
YoY Change -122.62% 141.07% -701.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.400M -4.000M 9.800M
YoY Change -34.69% -290.48% -56.64%
NET CHANGE
Cash From Operating Activities 40.40M 70.20M 50.60M
Cash From Investing Activities -10.20M -13.50M 45.10M
Cash From Financing Activities 6.400M -4.000M 9.800M
Net Change In Cash 36.60M 52.70M 105.5M
YoY Change -65.31% -11.73% 66.14%
FREE CASH FLOW
Cash From Operating Activities $40.40M $70.20M $50.60M
Capital Expenditures -$10.20M -$13.50M -$9.700M
Free Cash Flow $50.60M $83.70M $60.30M
YoY Change -16.09% 21.48% 15.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0000937556
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--01-02
CY2020Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1D
CY2020Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P3Y
CY2020Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P5Y
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-26
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33642
dei Entity Registrant Name
EntityRegistrantName
MASIMO CORP
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0368882
dei Entity Address Address Line1
EntityAddressAddressLine1
52 Discovery
dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92618
dei City Area Code
CityAreaCode
(949)
dei Local Phone Number
LocalPhoneNumber
297-7000
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
MASI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55055219 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
669056000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
567687000 USD
CY2020Q3 us-gaap Short Term Investments
ShortTermInvestments
50000000 USD
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
120000000 USD
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1615000 USD
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1803000 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
146859000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
132433000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
204779000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
115871000 USD
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
88272000 USD
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
60071000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
1158966000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
996062000 USD
CY2020Q3 us-gaap Net Investment In Lease Noncurrent
NetInvestmentInLeaseNoncurrent
56212000 USD
CY2019Q4 us-gaap Net Investment In Lease Noncurrent
NetInvestmentInLeaseNoncurrent
49936000 USD
CY2020Q3 us-gaap Deferred Costs
DeferredCosts
18566000 USD
CY2019Q4 us-gaap Deferred Costs
DeferredCosts
16214000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
267160000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
219552000 USD
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
57306000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
27251000 USD
CY2020Q3 us-gaap Goodwill
Goodwill
80220000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
22350000 USD
CY2020Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
36168000 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
35972000 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
38545000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
28791000 USD
CY2020Q3 us-gaap Assets
Assets
1713143000 USD
CY2019Q4 us-gaap Assets
Assets
1396128000 USD
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
89533000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
54548000 USD
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
58853000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
54705000 USD
CY2020Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
44542000 USD
CY2019Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
25939000 USD
CY2020Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
39824000 USD
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
37027000 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
232752000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
172219000 USD
CY2020Q3 us-gaap Deferred Credits And Other Liabilities
DeferredCreditsAndOtherLiabilities
65587000 USD
CY2019Q4 us-gaap Deferred Credits And Other Liabilities
DeferredCreditsAndOtherLiabilities
56035000 USD
CY2020Q3 us-gaap Liabilities
Liabilities
298339000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
228254000 USD
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1.000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1.000
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2019Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1.000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1.000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55055000 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53696000 shares
CY2020Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
55000 USD
CY2019Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
54000 USD
CY2020Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
15534000 shares
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
15530000 shares
CY2020Q3 us-gaap Treasury Stock Value
TreasuryStockValue
527171000 USD
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
526580000 USD
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
676568000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
600624000 USD
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-5214000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-6718000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1270566000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1100494000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
1414804000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1167874000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1713143000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1396128000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
278112000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
228916000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
848690000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
688974000 USD
CY2020Q3 masi Royaltyrevenueandother
Royaltyrevenueandother
0 USD
CY2019Q3 masi Royaltyrevenueandother
Royaltyrevenueandother
95000 USD
masi Royaltyrevenueandother
Royaltyrevenueandother
0 USD
masi Royaltyrevenueandother
Royaltyrevenueandother
1353000 USD
CY2020Q3 us-gaap Revenues
Revenues
278112000 USD
CY2019Q3 us-gaap Revenues
Revenues
229011000 USD
us-gaap Revenues
Revenues
848690000 USD
us-gaap Revenues
Revenues
690327000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
99186000 USD
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
72743000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
292551000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
228078000 USD
CY2020Q3 us-gaap Gross Profit
GrossProfit
178926000 USD
CY2019Q3 us-gaap Gross Profit
GrossProfit
156268000 USD
us-gaap Gross Profit
GrossProfit
556139000 USD
us-gaap Gross Profit
GrossProfit
462249000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
90376000 USD
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
80354000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
278714000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
232718000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28852000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24282000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86971000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69872000 USD
CY2020Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
CY2019Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
474000 USD
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
119228000 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
104636000 USD
us-gaap Operating Expenses
OperatingExpenses
365211000 USD
us-gaap Operating Expenses
OperatingExpenses
302590000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
59698000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
51632000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
190928000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
159659000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1357000 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2723000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6108000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10138000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
61055000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
54355000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
197036000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
169797000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11650000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5270000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
27403000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26502000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
49405000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
49085000 USD
us-gaap Profit Loss
ProfitLoss
169633000 USD
us-gaap Profit Loss
ProfitLoss
143295000 USD
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.90
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.92
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.69
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.85
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.86
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.92
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.51
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54997000 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53535000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54543000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53367000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58280000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57262000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58033000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57055000 shares
CY2020Q3 us-gaap Profit Loss
ProfitLoss
49405000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
49085000 USD
us-gaap Profit Loss
ProfitLoss
169633000 USD
us-gaap Profit Loss
ProfitLoss
143295000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2653000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1310000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1504000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1595000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
52058000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
47775000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
171137000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
141700000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1167874000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13495000 USD
CY2020Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1424000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11272000 USD
CY2020Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
371000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
64456000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
64456000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2463000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1253278000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21213000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13188000 USD
CY2020Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
220000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
55772000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
55772000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1314000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1344545000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6314000 USD
CY2020Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
25000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11912000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
49405000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
49405000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2653000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1414804000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
969065000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6867000 USD
CY2019Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
123000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7317000 USD
CY2019Q1 us-gaap Profit Loss
ProfitLoss
49322000 USD
CY2019Q1 us-gaap Profit Loss
ProfitLoss
49322000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-577000 USD
CY2019Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1005076000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5999000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11473000 USD
CY2019Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
27854000 USD
CY2019Q2 us-gaap Profit Loss
ProfitLoss
44888000 USD
CY2019Q2 us-gaap Profit Loss
ProfitLoss
44888000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
292000 USD
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1039874000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9925000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10855000 USD
CY2019Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
70000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
49085000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
49085000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1310000 USD
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1108359000 USD
us-gaap Profit Loss
ProfitLoss
169633000 USD
us-gaap Profit Loss
ProfitLoss
143295000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21200000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
151416000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17569000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
36372000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
29645000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-202000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-149000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
5000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
678000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
136000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-19000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9459000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
21697000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
86815000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
15221000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
23461000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
12060000 USD
us-gaap Proceeds From Lease Payments
ProceedsFromLeasePayments
-6279000 USD
us-gaap Proceeds From Lease Payments
ProceedsFromLeasePayments
-9396000 USD
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
1964000 USD
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-8901000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
775000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
68000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
31793000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1223000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
3654000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-975000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4691000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
389000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-2756000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
3430000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
9973000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
6760000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
395000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1259000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
146545000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
56064000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
5763000 USD
us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
-70000000 USD
us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
120000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
60017000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2968000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
78310000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
6750000 USD
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
5189000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-80840000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-184221000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
40994000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
22706000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1449000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
123000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
591000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
38954000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
27924000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5341000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-294000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-983000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
104365000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-39129000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
568075000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
552641000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
672440000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
513512000 USD
us-gaap Nature Of Operations
NatureOfOperations
<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1. Description of the Company </span></div><div style="margin-top:4.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Masimo Corporation (the Company) is a global medical technology company that develops, manufactures and markets a wide array of patient monitoring technologies, as well as automation and connectivity solutions. The Company’s mission is to improve patient outcomes and reduce the cost of patient care. The Company’s patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. The Company primarily sells its products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long term care facilities and consumers through its direct sales force, distributors and original equipment manufacturer (OEM) partners.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company invented Masimo Signal Extraction Technology</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">® </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(SET</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">), which provides the capabilities of Measure-through Motion and Low Perfusion</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">™</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> pulse oximetry to address the primary limitations of conventional pulse oximetry. Over the years, the Company’s product offerings have expanded significantly to also include rainbow</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Pulse CO-Oximetry, with its ability to monitor carboxyhemoglobin (SpCO</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">), methemoglobin (SpMet</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">), total hemoglobin concentration (SpHb</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">), fractional arterial oxygen saturation (SpfO</span><sub style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:bottom;">2</sub><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">™</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">), Oxygen Content (SpOC</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">™</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">), Pleth Variability Index (PVi</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">), rainbow</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Pleth Variability Index (RPVi</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">™</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">), respiration rate from the pleth (RRp</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) and Oxygen Reserve Index (ORi</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">™</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">); as well as acoustic respiration monitoring (RRa</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">), SedLine</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> brain function monitoring, NomoLine</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> capnography and gas monitoring and O3</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Regional Oximetry. These technologies are based upon Masimo SET</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, rainbow</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and other proprietary algorithms and are incorporated into a variety of product platforms depending on customers’ specifications. The Company’s current technology offerings also include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">™(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, Masimo Patient SafetyNet</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">™</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Surveillance</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, Masimo SafetyNet</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">™</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, Masimo SafetyNet-Open</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">™</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, Replica</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">™</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, Iris</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, MyView</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, UniView</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">™</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> UniView:60</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">™</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, Trace</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">™</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Masimo Sleep</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">™</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, Centroid</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">™</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and Bridge</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;vertical-align:top;">™</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company’s technologies are supported by a substantial intellectual property portfolio that the Company has built through internal development and, to a lesser extent, acquisitions and license agreements.</span></div>
us-gaap Maturity Of Time Deposits
MaturityOfTimeDeposits
P1M
us-gaap Fiscal Period
FiscalPeriod
<div style="text-indent:11.25pt;margin-top:13pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fiscal Periods</span></div><div style="margin-top:4.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company follows a conventional 52/53 week fiscal year. Under a conventional 52/53 week fiscal year, a 52 week fiscal year includes four quarters of 13 weeks while a 53 week fiscal year includes three 13 week fiscal quarters and one 14 week fiscal quarter. The Company’s last 53 week fiscal year was fiscal year 2014. Fiscal year 2020 is a 53 week fiscal year ending January 2, 2021, with the fourth quarter having 14 weeks. All references to years in these notes to condensed consolidated financial statements are fiscal years unless otherwise noted.</span></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="text-indent:11.25pt;margin-top:13pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reclassifications </span></div><div style="margin-top:4.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain amounts in the accompanying condensed consolidated financial statements have been reclassified to conform to the current period presentation.</span></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-indent:11.25pt;margin-top:13pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-top:4.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company prepares its financial statements in conformity with GAAP, which requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include the determination of standalone selling prices, variable consideration, total consideration allocated to each performance obligation within a contract, inventory valuation, valuation of the Company’s equity awards, valuation of identifiable assets and liabilities connected with business combinations, deferred taxes and any associated valuation allowances, deferred revenue, uncertain income tax positions, and litigation costs and related accruals. Actual results could differ from such estimates.</span></div>
CY2020Q3 us-gaap Short Term Investments
ShortTermInvestments
50000000.0 USD
masi Numberof Sourcesof Product Revenue
NumberofSourcesofProductRevenue
4 segment
CY2019Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
3395000 USD
CY2018Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1910000 USD
us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
428000 USD
us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
1920000 USD
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
-97000 USD
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
1404000 USD
us-gaap Product Warranty Expense
ProductWarrantyExpense
883000 USD
us-gaap Product Warranty Expense
ProductWarrantyExpense
1276000 USD
CY2020Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2843000 USD
CY2019Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
3958000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
49405000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
49085000 USD
us-gaap Net Income Loss
NetIncomeLoss
169633000 USD
us-gaap Net Income Loss
NetIncomeLoss
143295000 USD
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54997000 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53535000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54543000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53367000 shares
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.90
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.92
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.69
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54997000 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53535000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54543000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53367000 shares
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3283000 shares
CY2019Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3727000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3490000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3688000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58280000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57262000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58033000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57055000 shares
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.85
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.86
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.92
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.51
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
100000 shares
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
400000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
300000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
300000 shares
us-gaap Interest Paid Net
InterestPaidNet
194000 USD
us-gaap Interest Paid Net
InterestPaidNet
134000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
35961000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
34123000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
4699000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
5076000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
9900000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
25965000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3988000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4170000 USD
masi Settlementofpromissorynoteinconnectionwithacquisitionoptionexercise
Settlementofpromissorynoteinconnectionwithacquisitionoptionexercise
5100000 USD
masi Settlementofpromissorynoteinconnectionwithacquisitionoptionexercise
Settlementofpromissorynoteinconnectionwithacquisitionoptionexercise
0 USD
masi Proceedsfromstockoptionsexercisedunsettledatperiodend
Proceedsfromstockoptionsexercisedunsettledatperiodend
27000 USD
masi Proceedsfromstockoptionsexercisedunsettledatperiodend
Proceedsfromstockoptionsexercisedunsettledatperiodend
0 USD
masi Fairvalueofcommonstockreceivedforpaymentofstockoptionexerciseprice
Fairvalueofcommonstockreceivedforpaymentofstockoptionexerciseprice
220000 USD
masi Fairvalueofcommonstockreceivedforpaymentofstockoptionexerciseprice
Fairvalueofcommonstockreceivedforpaymentofstockoptionexerciseprice
0 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
669056000 USD
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
513360000 USD
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
3384000 USD
CY2019Q3 us-gaap Restricted Cash
RestrictedCash
152000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
672440000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
513512000 USD
masi Property Plantand Equipment Occupied Square Feet
PropertyPlantandEquipmentOccupiedSquareFeet
16830 sqft
CY2020Q3 masi Estimateof Annual Preventable Hospital Deaths Preventedby2020
EstimateofAnnualPreventableHospitalDeathsPreventedby2020
200000 death
CY2020Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
200000 USD
CY2020Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
200000 USD
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
3500000 USD
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
11746000 USD
CY2020Q3 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
22447000 USD
CY2020Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
119450000 USD
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
55913000 USD
CY2020Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
18297000 USD
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
10966000 USD
CY2020Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
67032000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
48992000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
204779000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
115871000 USD
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
29467000 USD
CY2019Q4 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
20250000 USD
CY2020Q3 us-gaap Prepaid Taxes
PrepaidTaxes
13636000 USD
CY2019Q4 us-gaap Prepaid Taxes
PrepaidTaxes
7330000 USD
CY2020Q3 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
9833000 USD
CY2019Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
9311000 USD
CY2020Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
3230000 USD
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
230000 USD
CY2020Q3 us-gaap Prepaid Royalties
PrepaidRoyalties
2930000 USD
CY2019Q4 us-gaap Prepaid Royalties
PrepaidRoyalties
1801000 USD
CY2020Q3 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
1936000 USD
CY2019Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
4847000 USD
CY2020Q3 masi Unbilled Contract Receivablecurrent
UnbilledContractReceivablecurrent
1850000 USD
CY2019Q4 masi Unbilled Contract Receivablecurrent
UnbilledContractReceivablecurrent
1486000 USD
CY2020Q3 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
2943000 USD
CY2019Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
3070000 USD
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
88272000 USD
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
60071000 USD
CY2020Q3 us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
13000000.0 USD
CY2019Q3 us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
11000000.0 USD
us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
31000000.0 USD
us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
33000000.0 USD
CY2020Q3 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived
78856000 USD
CY2019Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived
70589000 USD
CY2020Q3 masi Salestypelease Allowancefor Credit Loss
SalestypeleaseAllowanceforCreditLoss
197000 USD
CY2019Q4 masi Salestypelease Allowancefor Credit Loss
SalestypeleaseAllowanceforCreditLoss
403000 USD
CY2020Q3 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
78659000 USD
CY2019Q4 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
70186000 USD
CY2020Q3 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
22447000 USD
CY2019Q4 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
20250000 USD
CY2020Q3 us-gaap Net Investment In Lease Noncurrent
NetInvestmentInLeaseNoncurrent
56212000 USD
CY2019Q4 us-gaap Net Investment In Lease Noncurrent
NetInvestmentInLeaseNoncurrent
49936000 USD
CY2020Q3 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths
5903000 USD
CY2020Q3 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Two Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears
21706000 USD
CY2020Q3 masi Prepaid Discount
PrepaidDiscount
7757000 USD
CY2020Q3 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Three Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears
18399000 USD
CY2020Q3 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Four Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears
13957000 USD
CY2020Q3 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Five Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears
9964000 USD
CY2020Q3 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Thereafter
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter
8730000 USD
CY2020Q3 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
78659000 USD
CY2019Q4 masi Prepaid Discount
PrepaidDiscount
8098000 USD
CY2020Q3 masi Deferred Sales Commissions
DeferredSalesCommissions
6392000 USD
CY2019Q4 masi Deferred Sales Commissions
DeferredSalesCommissions
5260000 USD
CY2020Q3 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
3753000 USD
CY2019Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
2482000 USD
CY2020Q3 masi Equipmentleasedtocustomers
Equipmentleasedtocustomers
664000 USD
CY2019Q4 masi Equipmentleasedtocustomers
Equipmentleasedtocustomers
374000 USD
CY2020Q3 us-gaap Deferred Costs And Other Assets
DeferredCostsAndOtherAssets
18566000 USD
CY2019Q4 us-gaap Deferred Costs And Other Assets
DeferredCostsAndOtherAssets
16214000 USD
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
396268000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
332654000 USD
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
129108000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
113102000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
267160000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
219552000 USD
CY2020Q3 us-gaap Depreciation
Depreciation
5800000 USD
CY2019Q3 us-gaap Depreciation
Depreciation
4800000 USD
us-gaap Depreciation
Depreciation
16000000.0 USD
us-gaap Depreciation
Depreciation
14300000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
91527000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
57399000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
34221000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
30148000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
57306000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
27251000 USD
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P12Y
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1600000 USD
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5200000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3300000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
7083000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
7011000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
5691000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
5243000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
4880000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
27398000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
57306000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
22350000 USD
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
56427000 USD
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
1443000 USD
CY2020Q3 us-gaap Goodwill
Goodwill
80220000 USD
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.027
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26825000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19137000 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4957000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4653000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23600000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15834000 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
28557000 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
20487000 USD
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y8M12D
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1372000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5532000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4417000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4132000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
3175000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
13158000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
31786000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3229000 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
28557000 USD
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1776000 USD
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1717000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
5188000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
5170000 USD
CY2020Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0 USD
CY2019Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
1000 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
12000 USD
CY2020Q3 us-gaap Sublease Income
SubleaseIncome
0 USD
CY2019Q3 us-gaap Sublease Income
SubleaseIncome
52000 USD
us-gaap Sublease Income
SubleaseIncome
0 USD
us-gaap Sublease Income
SubleaseIncome
156000 USD
CY2020Q3 us-gaap Lease Cost
LeaseCost
1776000 USD
CY2019Q3 us-gaap Lease Cost
LeaseCost
1665000 USD
us-gaap Lease Cost
LeaseCost
5189000 USD
us-gaap Lease Cost
LeaseCost
5026000 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26825000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19137000 USD
CY2020Q3 us-gaap Equity Method Investments
EquityMethodInvestments
7950000 USD
CY2019Q4 us-gaap Equity Method Investments
EquityMethodInvestments
6475000 USD
CY2020Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
3616000 USD
CY2019Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
3022000 USD
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
154000 USD
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
157000 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
38545000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
28791000 USD
CY2020Q3 us-gaap Deferred Revenue
DeferredRevenue
31588000 USD
CY2019Q4 us-gaap Deferred Revenue
DeferredRevenue
13998000 USD
CY2020Q3 masi Accruedrebatesandallowances
Accruedrebatesandallowances
11389000 USD
CY2019Q4 masi Accruedrebatesandallowances
Accruedrebatesandallowances
8436000 USD
CY2020Q3 us-gaap Accounts Payable Other Current And Noncurrent
AccountsPayableOtherCurrentAndNoncurrent
5294000 USD
CY2019Q4 us-gaap Accounts Payable Other Current And Noncurrent
AccountsPayableOtherCurrentAndNoncurrent
5739000 USD
CY2020Q3 us-gaap Other Liabilities And Deferred Revenue Noncurrent
OtherLiabilitiesAndDeferredRevenueNoncurrent
48271000 USD
CY2019Q4 us-gaap Other Liabilities And Deferred Revenue Noncurrent
OtherLiabilitiesAndDeferredRevenueNoncurrent
28173000 USD
CY2020Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3729000 USD
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2234000 USD
CY2020Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
44542000 USD
CY2019Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
25939000 USD
CY2019Q4 us-gaap Deferred Revenue
DeferredRevenue
13998000 USD
masi Business Combination Deferred Revenue
BusinessCombinationDeferredRevenue
10064000 USD
us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
20058000 USD
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
12532000 USD
CY2020Q3 us-gaap Deferred Revenue
DeferredRevenue
31588000 USD
CY2020Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
222527000 USD
CY2020Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
359136000 USD
CY2020Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
166490000 USD
CY2020Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
34935000 USD
CY2020Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
783088000 USD
CY2020Q3 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
8049000 USD
CY2019Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
7545000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6545000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6115000 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4957000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4653000 USD
CY2020Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4391000 USD
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
7142000 USD
CY2020Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
3454000 USD
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
3024000 USD
CY2020Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
2843000 USD
CY2019Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
3395000 USD
CY2020Q3 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
2477000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
1839000 USD
CY2020Q3 masi Accrued Donations Current
AccruedDonationsCurrent
541000 USD
CY2019Q4 masi Accrued Donations Current
AccruedDonationsCurrent
966000 USD
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6567000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2348000 USD
CY2020Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
39824000 USD
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
37027000 USD
CY2020Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1900000 USD
CY2019Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1700000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23600000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15834000 USD
CY2020Q3 masi Income Tax Payable Noncurrent
IncomeTaxPayableNoncurrent
19245000 USD
CY2019Q4 masi Income Tax Payable Noncurrent
IncomeTaxPayableNoncurrent
21509000 USD
CY2020Q3 masi Unrecognized Tax Benefits Liabilities Noncurrent
UnrecognizedTaxBenefitsLiabilitiesNoncurrent
15602000 USD
CY2019Q4 masi Unrecognized Tax Benefits Liabilities Noncurrent
UnrecognizedTaxBenefitsLiabilitiesNoncurrent
13184000 USD
CY2020Q3 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
3190000 USD
CY2019Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
3052000 USD
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3950000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2456000 USD
CY2020Q3 us-gaap Deferred Credits And Other Liabilities
DeferredCreditsAndOtherLiabilities
65587000 USD
CY2019Q4 us-gaap Deferred Credits And Other Liabilities
DeferredCreditsAndOtherLiabilities
56035000 USD
CY2020Q3 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
4700000 USD
CY2020Q3 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
0 shares
CY2019Q3 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
1000 shares
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
4000 shares
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
208000 shares
CY2020Q3 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
0
CY2019Q3 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
139.91
us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
164.44
us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
134.05
CY2020Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
0 USD
CY2019Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
70000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
591000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
27924000 USD
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
70.68
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
11900000 USD
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
10900000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
36400000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
29600000 USD
CY2020Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11800000 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4400000 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5212000 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
54.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
387000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
186.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
199000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
125.70
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1316000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
31.17
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4084000 shares
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.019
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2602000 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
43.35
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
three years
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.002
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.003
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.014
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.014
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.002
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.017
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.026
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y1M6D
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y2M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y2M12D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.327
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.336
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.287
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.293
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.269
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.355
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.283
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.300
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
66.24
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
44.14
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
50.39
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
42.01
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
634300000 USD
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
475000000.0 USD
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
17900000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
215400000 USD
CY2020Q3 us-gaap Interest Income Other
InterestIncomeOther
797000 USD
CY2019Q3 us-gaap Interest Income Other
InterestIncomeOther
3664000 USD
us-gaap Interest Income Other
InterestIncomeOther
5120000 USD
us-gaap Interest Income Other
InterestIncomeOther
10706000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
84000 USD
CY2019Q3 us-gaap Interest Expense
InterestExpense
82000 USD
us-gaap Interest Expense
InterestExpense
250000 USD
us-gaap Interest Expense
InterestExpense
243000 USD
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
647000 USD
CY2019Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-856000 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1246000 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-315000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1357000 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2723000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6108000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10138000 USD
CY2020Q3 us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
3100000 USD
CY2019Q3 us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
7000000.0 USD
us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
20200000 USD
us-gaap Other Tax Expense Benefit
OtherTaxExpenseBenefit
13100000 USD
CY2020Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
19300000 USD
CY2020Q3 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
17800000 USD
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.03
CY2020Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
800000 USD
CY2019Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
700000 USD
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
2400000 USD
CY2020Q3 masi Severance Plan Participation Agreements
SeverancePlanParticipationAgreements
8 Agreement
masi Supplemental Unemployment Benefits Severance Benefits Required Noticeof Resignation
SupplementalUnemploymentBenefitsSeveranceBenefitsRequiredNoticeofResignation
P6M
CY2020Q3 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
162100000 USD
CY2020Q3 us-gaap Other Commitment
OtherCommitment
2600000 USD
CY2020Q3 masi Bank Balances
BankBalances
719100000 USD
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1900000 USD
CY2020Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
4400000 USD
CY2020Q3 masi Percentage Of Revenue One Customer
PercentageOfRevenueOneCustomer
0.110
CY2020Q3 masi Percentage Of Revenue Two Customer
PercentageOfRevenueTwoCustomer
0.093
CY2019Q3 masi Percentage Of Revenue One Customer
PercentageOfRevenueOneCustomer
0.106
CY2019Q3 masi Percentage Of Revenue Two Customer
PercentageOfRevenueTwoCustomer
0.126
masi Percentage Of Revenue One Customer
PercentageOfRevenueOneCustomer
0.112
masi Percentage Of Revenue Two Customer
PercentageOfRevenueTwoCustomer
0.100
masi Percentage Of Revenue One Customer
PercentageOfRevenueOneCustomer
0.110
masi Percentage Of Revenue Two Customer
PercentageOfRevenueTwoCustomer
0.132
CY2020Q3 masi Concentration Risk Ar Customer
ConcentrationRiskARCustomer
1 Customer
CY2019Q3 us-gaap Loss Contingency Damages Awarded Value
LossContingencyDamagesAwardedValue
10500000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
278112000 USD
CY2020Q3 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1.000
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
228916000 USD
CY2019Q3 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1.000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
848690000 USD
us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1.000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
688974000 USD
us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1.000
CY2020Q3 us-gaap Noncurrent Assets
NoncurrentAssets
267824000 USD
CY2020Q3 masi Concentration Risk Longlived Asset Geographic Area Percentage
ConcentrationRiskLonglivedAssetGeographicAreaPercentage
1.000
CY2019Q4 us-gaap Noncurrent Assets
NoncurrentAssets
219926000 USD
CY2019Q4 masi Concentration Risk Longlived Asset Geographic Area Percentage
ConcentrationRiskLonglivedAssetGeographicAreaPercentage
1.000

Files In Submission

Name View Source Status
0000937556-20-000171-index-headers.html Edgar Link pending
0000937556-20-000171-index.html Edgar Link pending
0000937556-20-000171.txt Edgar Link pending
0000937556-20-000171-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
masi-20200926.htm Edgar Link pending
masi-20200926.xsd Edgar Link pending
masi-20200926x10qex311.htm Edgar Link pending
masi-20200926x10qex312.htm Edgar Link pending
masi-20200926x10qex321.htm Edgar Link pending
masi-20200926_cal.xml Edgar Link unprocessable
masi-20200926_def.xml Edgar Link unprocessable
masi-20200926_g1.jpg Edgar Link pending
masi-20200926_htm.xml Edgar Link completed
masi-20200926_lab.xml Edgar Link unprocessable
masi-20200926_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending